Agenus Inc. (NASDAQ:AGEN) Scheduled to Post Quarterly Earnings on Wednesday
Agenus Inc. (NASDAQ:AGEN) will post its quarterly earnings results before the market opens on Wednesday, July 26th. Analysts expect Agenus to post earnings of ($0.38) per share for the quarter.
Agenus (NASDAQ:AGEN) last posted its quarterly earnings results on Thursday, May 4th. The biotechnology company reported ($0.18) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.32) by $0.14. The business had revenue of $26.96 million during the quarter, compared to the consensus estimate of $5.22 million. Agenus had a negative net margin of 257.79% and a negative return on equity of 37,577.49%. On average, analysts expect Agenus to post $-1.23 EPS for the current fiscal year and $-1.39 EPS for the next fiscal year.
Agenus Inc. (NASDAQ AGEN) opened at 5.00 on Wednesday. Agenus Inc. has a 1-year low of $3.20 and a 1-year high of $7.49. The firm’s market cap is $495.59 million. The firm has a 50 day moving average of $3.84 and a 200 day moving average of $3.85.
A number of equities analysts have recently commented on the stock. ValuEngine downgraded shares of Agenus from a “sell” rating to a “strong sell” rating in a research note on Saturday, July 8th. Zacks Investment Research raised shares of Agenus from a “sell” rating to a “buy” rating and set a $4.50 target price on the stock in a research note on Wednesday, July 5th. HC Wainwright set a $5.00 target price on shares of Agenus and gave the company a “hold” rating in a research note on Saturday, May 6th. Finally, Maxim Group reissued a “buy” rating and issued a $7.00 target price on shares of Agenus in a research note on Sunday, April 23rd. One research analyst has rated the stock with a sell rating, one has given a hold rating and four have issued a buy rating to the stock. Agenus presently has a consensus rating of “Buy” and a consensus target price of $5.88.
ILLEGAL ACTIVITY NOTICE: “Agenus Inc. (NASDAQ:AGEN) Scheduled to Post Quarterly Earnings on Wednesday” was first posted by American Banking News and is the property of of American Banking News. If you are viewing this story on another site, it was illegally stolen and reposted in violation of international copyright and trademark legislation. The original version of this story can be viewed at https://www.americanbankingnews.com/2017/07/19/agenus-inc-nasdaqagen-scheduled-to-post-quarterly-earnings-on-wednesday.html.
Agenus Inc (Agenus) is an immuno-oncology (I-O) company. The Company focuses on the discovery and development of therapies that engage the body’s immune system to fight cancer. It is developing a I-O portfolio driven by platforms and programs, such as antibody discovery platforms, including Retrocyte Display, SECANT yeast display and phage display technologies designed to produce human antibodies; antibody candidate programs, including checkpoint modulator (CPM) programs; vaccine programs, including Prophage, AutoSynVax and PhosPhoSynVax, and saponin-based vaccine adjuvants, principally QS-21 Stimulon adjuvant (QS-21 Stimulon).
Receive News & Ratings for Agenus Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agenus Inc. and related companies with MarketBeat.com's FREE daily email newsletter.